Back

Three-year follow-up of anthracycline-induced cardiotoxicity risk in breast cancer patients using the HFA-ICOS score

21 June 2025 (16:05 - 16:50)
Organised by: Logo
Congress Presentation Part of: Who is at risk of cardiovascular toxicity? Stratification, Prevention and Monitoring CCO Premium Access ESC Cardio-Oncology 2025 Council of Cardio-Oncology

About the speaker

Photo
Doctor Aiganym Amanova

Aktobe (Kazakhstan)

6 More presentations in this session

Presentation thumbnail
Cancer risks in heart failure patients: Insights from ischemic and non-ischemic cardiomyopathy
Doctor S. Kim (Seoul, KR)
Abstract Slides
Presentation thumbnail
Unrecognized cardiovascular risks in young cervical cancer patients. Findings from the Rebuc study
Doctor J. Hytting (Norrkoping, SE)
Abstract Slides
Presentation thumbnail
Framingham risk score associates with incident cancer and heart failure
Doctor F. Van Den Berg (Rotterdam, NL)
Abstract Slides
Presentation thumbnail
Predictive capacity of the HFA-ICOS risk stratification scale for cardiovascular adverse events in patients treated with proteasome inhibitors
Mr E. Pons-Fuster Lopez (Murcia, ES)
Abstract Slides
Presentation thumbnail
Prognostic value of HFA-PEFF and H2FPEF scores in patients with advanced cancer: a prospective observational study
Ms I. Baluta (Berlin, DE)
Abstract Slides

Access the full session

Session thumbnail
Who is at risk of cardiovascular toxicity?

The Event

Event poster

ESC Cardio-Oncology 2025

21 June 2025 16:05 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources